EndoProtech has two additional patents for therapies to treat inflammation in alcoholic liver disease and ischemia/reperfusion injury in transplantation of organs. The company has developed both products to the proof-of-concept stage. The therapy to treat alcoholic liver disease is in the early stages of the regulatory process.

 

A Novel Approach to ReduceInfarct Size FollowingMyocardial Infarction

 

EndoGuard: Is a novel therapy designed to treat cardiac microvascular obstruction (no-reflow phenomenon) following revascularization of the occluded coronary artery. Preclinical studies have demonstrated that intracoronary administration of EndoGuard just prior to reperfusion reduced myocardial infarct size by approximately 50%. The drug is indicated for use as an adjuvant to percutaneous coronary intervention (PCI) to treat patients with ST segment-elevation myocardial infarction (STEMI).

 

 

Looking atLiver Diseasea Whole New Way

 

Endohepal: Is a liposomal-rolipram therapy designed to treat alcoholic hepatitis while reducing the well-known side effects that phosphodiesterase 4 inhibitors produce. Preclinical studies have demonstrated the ability of the drug to reduce liver inflammation and alcohol-related steatosis.

Related Publications and Research:

View PDF

Stabilizing the endothelium of donor hearts with

fusogenic liposomes reduces myocardial injury and dysfunction

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3619012/

View PDF

Enhancing complement control on endothelial barrier

reduces renal post-ischemia dysfunction

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3175310/

View PDF

A novel liposome-based therapy to reduce complement-mediated

injury in revascularized tissues

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3005705/

Patents

Cell-surface Decoration with Active Agents. Japanese Patent No. 5264478; New Zealand Patent No. 562946; Australian Patent No. 2006 242354; Canadian Patent No. 2,605,863; Great Britain Patent No. 1877038, Germany Patent No. 602006052042.5, and France Patent No. 1877038; US Patent Application No. 11/912,985, and PCT Publication WO2006/119121.

Research Pipeline...

Contact Us

Required

Required

Submitting Form...

The server encountered an error.

Form received.

Required

Required

1044 E. Chestnut St

Louisville, KY 40204-1019

 

Phone: 502-742-8555

Toll Free: 1-844-662-2249

Fax: 502-315-3201

©2019 EndoProtech Inc.

All rights reserved.

Website by:

Taylor Advertising LLC

MENU

Research Pipeline...

View PDF

Stabilizing the endothelium of donor hearts with fusogenic liposomes reduces myocardial injury and dysfunction

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3619012/

View PDF

Enhancing complement control on endothelial barrier reduces renal post-ischemia dysfunction

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3175310/

View PDF

A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3005705/

EndoProtech has two additional patents for therapies to treat inflammation in alcoholic liver disease and ischemia/reperfusion injury in transplantation of organs. The company has developed both products to the proof-of-concept stage. The therapy to treat alcoholic liver disease is in the early stages of the regulatory process.

 

A Novel Approach to ReduceInfarct Size FollowingMyocardial Infarction

 

EndoGuard: Is a novel therapy designed to treat cardiac microvascular obstruction (no-reflow phenomenon) following revascularization of the occluded coronary artery. Preclinical studies have demonstrated that intracoronary administration of EndoGuard just prior to reperfusion reduced myocardial infarct size by approximately 50%. The drug is indicated for use as an adjuvant to percutaneous coronary intervention (PCI) to treat patients with ST segment-elevation myocardial infarction (STEMI).

 

 

Looking atLiver Diseasea Whole New Way

 

Endohepal: Is a liposomal-rolipram therapy designed to treat alcoholic hepatitis while reducing the well-known side effects that phosphodiesterase 4 inhibitors produce. Preclinical studies have demonstrated the ability of the drug to reduce liver inflammation and alcohol-related steatosis.